Effects of extensive passaging on the characteristics of pancreatic ductal adenocarcinoma cancer cell line HG008-T
Abstract
Pancreatic cancer is one of the major causes of cancer death. Pancreatic cancer cell lines are important for drug and cancer treatment development. In a collaborative effort, we established a novel Cancer Genome-in-a-Bottle cell line HG008-T from a pancreatic cancer patient explicitly consented to make public extensive genomic data, which was recently published. The HG008-T cell line is publicly available at ATCC as CRL-3734. Characterizing a cell line before it is available from a public repository is critical to ensure scientific reliability, and reproducibility. The cell line has known somatic variants in KRAS , TP53 , SMAD4 , and CDKN2A genes, and was derived from a patient who received platinum neoadjuvant therapy. To complement the extensive genomic characterization published recently, in this study we characterized HG008-T over 80 passages by comparing early-passage cells with late-passage cells. The cells were found to proliferate faster after extensive passaging and lost heterogeneity in morphology. Following extensive passaging, an increased proportion of cells exhibited whole-genome doubling (WGD), which may reflect the selective expansion of WGD clones due to enhanced proliferative capacity and/or de novo genome doubling events occurring in non-WGD cells during prolonged culture. The late-passage cells exhibited increased anchorage-independent growth. No significant surface marker expression alteration was observed. However, following approximately 80 passages, heterogeneous alterations in marker gene expression were observed. The late-passage cells were more sensitive to cisplatin but exhibited a modest shift in sensitivity to the CDK4/6 inhibitor palbociclib. In conclusion, extensive passaging altered certain characteristics of HG008-T cells, therefore, passage history should be indicated in future studies using HG008-T cell line as a cancer cell model.
Related
- Borderline resectable pancreatic ductal adenocarcinoma: a narrative review
- Combined halp and GRIm scores for risk stratification in metastatic pancreatic ductal adenocarcinoma
- Prognostic and Spatial Organization of Tertiary Lymphoid Structures in Pancreatic Ductal Adenocarcinoma
- Identification of miR-615-5p/ID1 axis crucial in the pathogenesis of pancreatic ductal adenocarcinoma (PDAC)
- Immunohistochemical Expression of M30, BCL-2, BAX, and Ki-67 in Pancreatic Ductal Adenocarcinoma: Association with Clinicopathological Features
BibTeX
@article{he2026effects,
title = {{Effects of extensive passaging on the characteristics of pancreatic ductal adenocarcinoma cancer cell line HG008-T}},
author = {Zhiyong He and Jerilyn R. Izac and Alexander A. Gooden and Edward Kwee and Andrew S. Liss and Justin M. Zook and Hua-Jun He},
journal = {Scientific Reports},
year = {2026},
month = sep,
doi = {10.1038/s41598-026-73171-w},
url = {https://www.nature.com/articles/s41598-026-73171-w},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Effects of extensive passaging on the characteristics of pancreatic ductal adenocarcinoma cancer cell line HG008-T
AU - Zhiyong He
AU - Jerilyn R. Izac
AU - Alexander A. Gooden
AU - Edward Kwee
AU - Andrew S. Liss
AU - Justin M. Zook
AU - Hua-Jun He
PY - 2026
DA - 2026/09/30
JO - Scientific Reports
DO - 10.1038/s41598-026-73171-w
UR - https://www.nature.com/articles/s41598-026-73171-w
AB - Pancreatic cancer is one of the major causes of cancer death. Pancreatic cancer cell lines are important for drug and cancer treatment development. In a collaborative effort, we established a novel Cancer Genome-in-a-Bottle cell line HG008-T from a pancreatic cancer patient explicitly consented to make public extensive genomic data, which was recently published. The HG008-T cell line is publicly available at ATCC as CRL-3734. Characterizing a cell line before it is available from a public repository is critical to ensure scientific reliability, and reproducibility. The cell line has known somatic variants in KRAS , TP53 , SMAD4 , and CDKN2A genes, and was derived from a patient who received platinum neoadjuvant therapy. To complement the extensive genomic characterization published recently, in this study we characterized HG008-T over 80 passages by comparing early-passage cells with late-passage cells. The cells were found to proliferate faster after extensive passaging and lost heterogeneity in morphology. Following extensive passaging, an increased proportion of cells exhibited whole-genome doubling (WGD), which may reflect the selective expansion of WGD clones due to enhanced proliferative capacity and/or de novo genome doubling events occurring in non-WGD cells during prolonged culture. The late-passage cells exhibited increased anchorage-independent growth. No significant surface marker expression alteration was observed. However, following approximately 80 passages, heterogeneous alterations in marker gene expression were observed. The late-passage cells were more sensitive to cisplatin but exhibited a modest shift in sensitivity to the CDK4/6 inhibitor palbociclib. In conclusion, extensive passaging altered certain characteristics of HG008-T cells, therefore, passage history should be indicated in future studies using HG008-T cell line as a cancer cell model.
SN - 2045-2322
ER -